Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arbutus Biopharma CorpABUS · Entity 4953 | Director · 10% owner | February 24, 2025 | March 06, 2025 |
| Roivant Sciences Ltd.ROIV · Entity 3185 | Director · CEO | September 30, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arbutus Biopharma Corp
Report date February 24, 2025 · Filed March 06, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | IndirectBy Roivant Sciences Ltd. | 38,847,462 |
Reported balance
Holding disclosure · report date 2025-02-24 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 38,847,462 F1: The Reporting Person is the Principal Executive Officer and a director of Roivant Sciences Ltd. (''Roivant'') and may be deemed to have beneficial ownership of the securities of the Issuer held by Roivant. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person is the Principal Executive Officer and a director of Roivant Sciences Ltd. (''Roivant'') and may be deemed to have beneficial ownership of the securities of the Issuer held by Roivant. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
Roivant Sciences Ltd.
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 16,583,774 |
Reported balance
After 2026-09-30 transaction · row 1
1 source rowRow 1 · 2026-09-30 · Tax withholding · Disposed 76,171 · Balance 16,583,774 F1: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2026 Filed Oct 3, 2026 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 76,171 | $36.57 | $2,785,573.47 |
DisclosureSEC source: 0001140361-26-038475 · form4.xml · nonDerivative · entry 1 Gline Matthew · CIK 0001750094 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,583,774 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 23:06 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 76,171 | $35.39 | $2,695,691.69 |
DisclosureSEC source: 0001635088-26-000079 · wk-form4_1783033560.xml · nonDerivative · entry 1 Gline Matthew · CIK 0001750094 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,659,945 F1 · balance_after: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| April 16, 2026 Filed Apr 20, 2026 22:27 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 289,774 | $29.16 | $8,449,809.84 |
DisclosureSEC source: 0001635088-26-000038 · wk-form4_1776724041.xml · nonDerivative · entry 1 Gline Matthew · CIK 0001750094 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,736,116 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.98 to $29.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. Read SEC document |
| March 31, 2026 Filed Apr 1, 2026 23:20 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 304,684 | $27.70 | $8,439,746.80 |
DisclosureSEC source: 0001635088-26-000034 · wk-form4_1775085629.xml · nonDerivative · entry 3 Gline Matthew · CIK 0001750094 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,025,890 F4 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| March 30, 2026 Filed Apr 1, 2026 23:20 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCapped Value Appreciation Rights · Derivative | 2,178,150 | $11.50 | $25,048,725.00 |
DisclosureSEC source: 0001635088-26-000034 · wk-form4_1775085629.xml · derivative · entry 4 Gline Matthew · CIK 0001750094 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 97,319 shares Expires 2026-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount"). F2 · derivative.exercise_price: On March 30, 2026, the hurdle price applicable to 2,178,150 vested CVARs was satisfied and, accordingly, the CVARs were settled into 97,319 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 30, 2026. F1 · shares: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount"). F2 · shares: On March 30, 2026, the hurdle price applicable to 2,178,150 vested CVARs was satisfied and, accordingly, the CVARs were settled into 97,319 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 30, 2026. F1 · derivative.exercise_date: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount"). F2 · derivative.exercise_date: On March 30, 2026, the hurdle price applicable to 2,178,150 vested CVARs was satisfied and, accordingly, the CVARs were settled into 97,319 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 30, 2026. F5 · derivative.exercise_date: Award of CVARs is fully vested. F1 · derivative.underlying_shares: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount"). F2 · derivative.underlying_shares: On March 30, 2026, the hurdle price applicable to 2,178,150 vested CVARs was satisfied and, accordingly, the CVARs were settled into 97,319 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 30, 2026. Read SEC document |
| March 30, 2026 Filed Apr 1, 2026 23:20 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 53,826 | $26.41 | $1,421,544.66 |
DisclosureSEC source: 0001635088-26-000034 · wk-form4_1775085629.xml · nonDerivative · entry 2 Gline Matthew · CIK 0001750094 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,330,574 F3 · kind: Represents the "net settlement" by the Issuer of CVARs in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such CVARs. Read SEC document |
| March 30, 2026 Filed Apr 1, 2026 23:20 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 97,319 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001635088-26-000034 · wk-form4_1775085629.xml · nonDerivative · entry 1 Gline Matthew · CIK 0001750094 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,384,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount"). F2 · kind: On March 30, 2026, the hurdle price applicable to 2,178,150 vested CVARs was satisfied and, accordingly, the CVARs were settled into 97,319 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 30, 2026. F1 · price: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount"). F2 · price: On March 30, 2026, the hurdle price applicable to 2,178,150 vested CVARs was satisfied and, accordingly, the CVARs were settled into 97,319 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 30, 2026. Read SEC document |
| December 15, 2025 Filed Dec 18, 2025 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,272,852 | $0.00 Strike: $12.68 | $0.00 |
DisclosureSEC source: 0001140361-25-045906 · form4.xml · derivative · entry 12 Gline Matthew · CIK 0001750094 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,272,852 shares Expires 2026-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Award of stock options to purchase Common Shares that is fully vested. Read SEC document |
| December 15, 2025 Filed Dec 18, 2025 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,363,711 | $0.00 Strike: $12.68 | $0.00 |
DisclosureSEC source: 0001140361-25-045906 · form4.xml · derivative · entry 11 Gline Matthew · CIK 0001750094 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,363,711 shares Expires 2026-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Award of stock options to purchase Common Shares that is fully vested. Read SEC document |
| December 15, 2025 Filed Dec 18, 2025 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 234,096 | $0.00 Strike: $4.06 | $0.00 |
DisclosureSEC source: 0001140361-25-045906 · form4.xml · derivative · entry 10 Gline Matthew · CIK 0001750094 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 234,096 shares Expires 2026-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Award of stock options to purchase Common Shares that is fully vested. Read SEC document |
| December 15, 2025 Filed Dec 18, 2025 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 1,329,325 | $21.68 | $28,819,766.00 |
DisclosureSEC source: 0001140361-25-045906 · form4.xml · nonDerivative · entry 9 Gline Matthew · CIK 0001750094 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,287,081 F2 · shares: Represents the "net settlement" by the Issuer of stock options previously granted to the reporting person in order to satisfy the exercise price applicable to such stock options. F1 · price: All options exercised by the reporting person would have expired in March or April 2026 if not exercised. The transactions reported on this Form 4 represent the disposition of the entirety of the reporting person's stock options expiring in 2026. As of the date of this filing, the reporting person has disgorged to the Issuer the full amount of the disgorgable profits realized from the sale reported herein, as required by Section 16(b) of the Securities Exchange Act of 1934. Read SEC document |
| December 15, 2025 Filed Dec 18, 2025 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 943,527 | $21.68 | $20,455,665.36 |
DisclosureSEC source: 0001140361-25-045906 · form4.xml · nonDerivative · entry 8 Gline Matthew · CIK 0001750094 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,616,406 F1 · price: All options exercised by the reporting person would have expired in March or April 2026 if not exercised. The transactions reported on this Form 4 represent the disposition of the entirety of the reporting person's stock options expiring in 2026. As of the date of this filing, the reporting person has disgorged to the Issuer the full amount of the disgorgable profits realized from the sale reported herein, as required by Section 16(b) of the Securities Exchange Act of 1934. Read SEC document |
| December 15, 2025 Filed Dec 18, 2025 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 2,272,852 | $12.68 | $28,819,763.36 |
DisclosureSEC source: 0001140361-25-045906 · form4.xml · nonDerivative · entry 7 Gline Matthew · CIK 0001750094 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,559,933 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2025 Filed Dec 18, 2025 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 797,595 | $21.68 | $17,291,859.60 |
DisclosureSEC source: 0001140361-25-045906 · form4.xml · nonDerivative · entry 6 Gline Matthew · CIK 0001750094 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,287,081 F2 · shares: Represents the "net settlement" by the Issuer of stock options previously granted to the reporting person in order to satisfy the exercise price applicable to such stock options. F1 · price: All options exercised by the reporting person would have expired in March or April 2026 if not exercised. The transactions reported on this Form 4 represent the disposition of the entirety of the reporting person's stock options expiring in 2026. As of the date of this filing, the reporting person has disgorged to the Issuer the full amount of the disgorgable profits realized from the sale reported herein, as required by Section 16(b) of the Securities Exchange Act of 1934. Read SEC document |
| December 15, 2025 Filed Dec 18, 2025 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 566,116 | $21.68 | $12,273,394.88 |
DisclosureSEC source: 0001140361-25-045906 · form4.xml · nonDerivative · entry 5 Gline Matthew · CIK 0001750094 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,084,676 F1 · price: All options exercised by the reporting person would have expired in March or April 2026 if not exercised. The transactions reported on this Form 4 represent the disposition of the entirety of the reporting person's stock options expiring in 2026. As of the date of this filing, the reporting person has disgorged to the Issuer the full amount of the disgorgable profits realized from the sale reported herein, as required by Section 16(b) of the Securities Exchange Act of 1934. Read SEC document |
| December 15, 2025 Filed Dec 18, 2025 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 1,363,711 | $12.68 | $17,291,855.48 |
DisclosureSEC source: 0001140361-25-045906 · form4.xml · nonDerivative · entry 4 Gline Matthew · CIK 0001750094 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,650,792 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2025 Filed Dec 18, 2025 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 3,739 | $21.68 | $81,061.52 |
DisclosureSEC source: 0001140361-25-045906 · form4.xml · nonDerivative · entry 3 Gline Matthew · CIK 0001750094 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,287,081 F2 · shares: Represents the "net settlement" by the Issuer of stock options previously granted to the reporting person in order to satisfy the exercise price applicable to such stock options. F1 · price: All options exercised by the reporting person would have expired in March or April 2026 if not exercised. The transactions reported on this Form 4 represent the disposition of the entirety of the reporting person's stock options expiring in 2026. As of the date of this filing, the reporting person has disgorged to the Issuer the full amount of the disgorgable profits realized from the sale reported herein, as required by Section 16(b) of the Securities Exchange Act of 1934. Read SEC document |
| December 15, 2025 Filed Dec 18, 2025 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 230,357 | $21.68 | $4,994,139.76 |
DisclosureSEC source: 0001140361-25-045906 · form4.xml · nonDerivative · entry 2 Gline Matthew · CIK 0001750094 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,290,820 F1 · price: All options exercised by the reporting person would have expired in March or April 2026 if not exercised. The transactions reported on this Form 4 represent the disposition of the entirety of the reporting person's stock options expiring in 2026. As of the date of this filing, the reporting person has disgorged to the Issuer the full amount of the disgorgable profits realized from the sale reported herein, as required by Section 16(b) of the Securities Exchange Act of 1934. Read SEC document |
| December 15, 2025 Filed Dec 18, 2025 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 234,096 | $4.06 | $950,429.76 |
DisclosureSEC source: 0001140361-25-045906 · form4.xml · nonDerivative · entry 1 Gline Matthew · CIK 0001750094 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,521,177 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 18, 2025 Filed Sep 18, 2025 23:28 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | PurchaseCommon Shares | 3,315 | $15.07 | $49,957.05 |
DisclosureSEC source: 0001140361-25-035435 · form4.xml · nonDerivative · entry 1 Gline Matthew · CIK 0001750094 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,287,081 F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares purchased at each separate price within the range. Read SEC document |
| May 20, 2025 Filed May 23, 2025 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 10,945 | $11.04 | $120,832.80 |
DisclosureSEC source: 0001140361-25-020240 · form4.xml · nonDerivative · entry 1 Gline Matthew · CIK 0001750094 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,283,766 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| April 20, 2025 Filed Apr 23, 2025 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 10,945 | $10.15 | $111,091.75 |
DisclosureSEC source: 0001140361-25-014985 · form4.xml · nonDerivative · entry 1 Gline Matthew · CIK 0001750094 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,294,711 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| March 20, 2025 Filed Mar 25, 2025 01:01 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 10,945 | $10.97 | $120,066.65 |
DisclosureSEC source: 0001140361-25-010117 · form4.xml · nonDerivative · entry 1 Gline Matthew · CIK 0001750094 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,305,656 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| February 20, 2025 Filed Feb 25, 2025 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 10,945 | $10.72 | $117,330.40 |
DisclosureSEC source: 0001140361-25-005718 · form4.xml · nonDerivative · entry 1 Gline Matthew · CIK 0001750094 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,316,601 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| January 20, 2025 Filed Jan 23, 2025 02:04 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 11,623 | $11.15 | $129,596.45 |
DisclosureSEC source: 0001140361-25-001661 · form4.xml · nonDerivative · entry 1 Gline Matthew · CIK 0001750094 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,327,546 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| December 20, 2024 Filed Dec 27, 2024 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 10,945 | $11.57 | $126,633.65 |
DisclosureSEC source: 0001140361-24-050457 · form4.xml · nonDerivative · entry 1 Gline Matthew · CIK 0001750094 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,339,169 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| November 20, 2024 Filed Nov 23, 2024 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 10,945 | $11.49 | $125,758.05 |
DisclosureSEC source: 0001140361-24-047696 · form4.xml · nonDerivative · entry 1 Gline Matthew · CIK 0001750094 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,350,114 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| October 20, 2024 Filed Oct 23, 2024 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 10,945 | $11.92 | $130,464.40 |
DisclosureSEC source: 0001140361-24-043960 · form4.xml · nonDerivative · entry 1 Gline Matthew · CIK 0001750094 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,361,059 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| September 23, 2024 Filed Sep 25, 2024 01:01 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,550,000 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001140361-24-041788 · form4.xml · derivative · entry 5 Gline Matthew · CIK 0001750094 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,973,184 Underlying: Common Stock · 1,550,000 shares Expires 2032-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). Read SEC document |
| September 23, 2024 Filed Sep 25, 2024 01:01 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 498,539 | $11.97 | $5,967,511.83 |
DisclosureSEC source: 0001140361-24-041788 · form4.xml · nonDerivative · entry 4 Gline Matthew · CIK 0001750094 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,372,004 F4 · shares: Represents the "net settlement" by the Issuer of options previously granted to the reporting person in order to satisfy the exercise price applicable to such options. Read SEC document |
| September 23, 2024 Filed Sep 25, 2024 01:01 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 1,983,257 | $11.79 | $23,382,600.03 |
DisclosureSEC source: 0001140361-24-041788 · form4.xml · nonDerivative · entry 3 Gline Matthew · CIK 0001750094 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,870,543 F2 · shares: The reporting person does not expect to sell additional shares of the Issuer in the near future. F3 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. Read SEC document |
| September 23, 2024 Filed Sep 25, 2024 01:01 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 1,550,000 | $3.85 | $5,967,500.00 |
DisclosureSEC source: 0001140361-24-041788 · form4.xml · nonDerivative · entry 2 Gline Matthew · CIK 0001750094 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,853,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 20, 2024 Filed Sep 25, 2024 01:01 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 10,945 | $11.97 | $131,011.65 |
DisclosureSEC source: 0001140361-24-041788 · form4.xml · nonDerivative · entry 1 Gline Matthew · CIK 0001750094 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,303,800 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| August 20, 2024 Filed Aug 23, 2024 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 10,947 | $11.48 | $125,671.56 |
DisclosureSEC source: 0001140361-24-038305 · form4.xml · nonDerivative · entry 1 Gline Matthew · CIK 0001750094 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,314,745 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| July 26, 2024 Filed Jul 31, 2024 01:04 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 14,450,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-24-011231 · dp2015708_4-gline.xml · nonDerivative · entry 2 Gline Matthew · CIK 0001750094 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,325,692 F2 · shares: Reflects an award of performance restricted stock units with respect to Common Shares ("PSUs") across six share price hurdle tranches, as follows: $15.00 (14.71% of PSUs); $17.50 (7.35% of PSUs); $20.00 (8.82% of PSUs); $22.50 (11.77% of PSUs); $25.00 (22.06% ofPSUs); and $30.00 (35.29% of PSUs). The PSUs will vest tranche-by-tranche on the first date that both the performance condition and the service condition with respect to the applicable tranche of the PSUs has been satisfied. The performance condition will be deemed satisfiedfor each tranche of PSUs on the first date, during the performance period ending on the five-year anniversary of the grant date, when the Company's trailing 30-day volume weighted average trading price per share exceeds the share price hurdle applicable to such tranche (asspecified above). F3 · shares: The service condition will be deemed satisfied for each tranche of PSUs on the first anniversary of the date on which the performance condition is first satisfied with respect to such tranche, subject to the reporting person's continuous service through such anniversary. Inaddition, following the satisfaction of the performance condition and service condition and the vesting of any tranche of the PSUs, the common shares underlying the applicable vested tranche of PSUs are subject to a further two-year holding period before such common sharesmay be sold. Read SEC document |
| July 26, 2024 Filed Jul 31, 2024 01:04 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 2,754,821 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-24-011231 · dp2015708_4-gline.xml · nonDerivative · entry 1 Gline Matthew · CIK 0001750094 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,875,692 F1 · shares: Reflects an award of restricted stock units with respect to Common Shares ("RSUs"), with a vesting commencement date of March 31, 2025, which service-vest (i) 20% on the first anniversary of the vesting commencement date and (ii) in 16 successive equal quarterly installments thereafter, subject to the reporting person's continuous service through the applicable vesting date. Read SEC document |
| July 20, 2024 Filed Jul 26, 2024 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 10,945 | $11.00 | $120,395.00 |
DisclosureSEC source: 0001140361-24-034284 · form4.xml · nonDerivative · entry 1 Gline Matthew · CIK 0001750094 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,120,871 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| June 20, 2024 Filed Jun 25, 2024 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 10,945 | $10.80 | $118,206.00 |
DisclosureSEC source: 0001140361-24-031173 · form4.xml · nonDerivative · entry 1 Gline Matthew · CIK 0001750094 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,131,816 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| May 20, 2024 Filed May 23, 2024 01:01 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 10,945 | $11.37 | $124,444.65 |
DisclosureSEC source: 0001140361-24-027206 · form4.xml · nonDerivative · entry 1 Gline Matthew · CIK 0001750094 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,142,761 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| April 20, 2024 Filed Apr 24, 2024 01:01 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 10,945 | $10.46 | $114,484.70 |
DisclosureSEC source: 0001140361-24-021495 · form4.xml · nonDerivative · entry 1 Gline Matthew · CIK 0001750094 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,153,706 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| March 30, 2024 Filed Apr 3, 2024 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCapped Value Appreciation Rights · Derivative | 994,373 | $6.40 | $6,363,987.20 |
DisclosureSEC source: 0001140361-24-017373 · form4.xml · derivative · entry 3 Gline Matthew · CIK 0001750094 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 390,579 shares Expires 2026-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount"). F2 · derivative.exercise_price: On March 30, 2024, the "knock-in" condition (as defined below) and hurdle price applicable to the remaining 994,373 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 390,579 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 28, 2024. F4 · derivative.exercise_price: This award of CVARs vested (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date, with a vesting commencement date of December 27, 2019. F1 · shares: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount"). F2 · shares: On March 30, 2024, the "knock-in" condition (as defined below) and hurdle price applicable to the remaining 994,373 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 390,579 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 28, 2024. F4 · shares: This award of CVARs vested (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date, with a vesting commencement date of December 27, 2019. F1 · price: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount"). F2 · price: On March 30, 2024, the "knock-in" condition (as defined below) and hurdle price applicable to the remaining 994,373 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 390,579 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 28, 2024. F1 · derivative.exercise_date: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount"). F2 · derivative.exercise_date: On March 30, 2024, the "knock-in" condition (as defined below) and hurdle price applicable to the remaining 994,373 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 390,579 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 28, 2024. F4 · derivative.exercise_date: This award of CVARs vested (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date, with a vesting commencement date of December 27, 2019. F1 · derivative.underlying_shares: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount"). F2 · derivative.underlying_shares: On March 30, 2024, the "knock-in" condition (as defined below) and hurdle price applicable to the remaining 994,373 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 390,579 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 28, 2024. Read SEC document |
| March 30, 2024 Filed Apr 3, 2024 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 215,991 | $10.54 | $2,276,545.14 |
DisclosureSEC source: 0001140361-24-017373 · form4.xml · nonDerivative · entry 2 Gline Matthew · CIK 0001750094 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,164,651 F3 · kind: Represents the "net settlement" by the Issuer of CVARs in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of the CVARs. Read SEC document |
| March 30, 2024 Filed Apr 3, 2024 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 390,579 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-24-017373 · form4.xml · nonDerivative · entry 1 Gline Matthew · CIK 0001750094 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,380,642 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount"). F2 · kind: On March 30, 2024, the "knock-in" condition (as defined below) and hurdle price applicable to the remaining 994,373 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 390,579 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 28, 2024. F1 · price: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount"). F2 · price: On March 30, 2024, the "knock-in" condition (as defined below) and hurdle price applicable to the remaining 994,373 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 390,579 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 28, 2024. Read SEC document |
| March 20, 2024 Filed Mar 23, 2024 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 10,945 | $10.01 | $109,559.45 |
DisclosureSEC source: 0001140361-24-014894 · form4.xml · nonDerivative · entry 1 Gline Matthew · CIK 0001750094 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 990,063 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| February 20, 2024 Filed Feb 23, 2024 02:01 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 10,945 | $11.54 | $126,305.30 |
DisclosureSEC source: 0001140361-24-009096 · form4.xml · nonDerivative · entry 1 Gline Matthew · CIK 0001750094 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,001,008 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| January 20, 2024 Filed Jan 24, 2024 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 10,945 | $10.35 | $113,280.75 |
DisclosureSEC source: 0001140361-24-003550 · form4.xml · nonDerivative · entry 1 Gline Matthew · CIK 0001750094 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,011,953 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| December 27, 2023 Filed Dec 30, 2023 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCapped Value Appreciation Rights · Derivative | 47,351 | $11.50 | $544,536.50 |
DisclosureSEC source: 0001140361-23-060293 · form4.xml · derivative · entry 4 Gline Matthew · CIK 0001750094 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,178,150 Underlying: Common Shares · 327 shares Expires 2026-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount"). F3 · derivative.exercise_price: On December 27, 2023, the hurdle price applicable to 47,351 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 327 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023. F5 · derivative.exercise_price: This award of CVARs vests (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date, with a vesting commencement date of December 27, 2019. F1 · shares: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount"). F3 · shares: On December 27, 2023, the hurdle price applicable to 47,351 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 327 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023. F5 · shares: This award of CVARs vests (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date, with a vesting commencement date of December 27, 2019. F1 · price: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount"). F3 · price: On December 27, 2023, the hurdle price applicable to 47,351 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 327 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023. F1 · derivative.exercise_date: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount"). F3 · derivative.exercise_date: On December 27, 2023, the hurdle price applicable to 47,351 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 327 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023. F5 · derivative.exercise_date: This award of CVARs vests (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date, with a vesting commencement date of December 27, 2019. F1 · derivative.underlying_shares: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount"). F3 · derivative.underlying_shares: On December 27, 2023, the hurdle price applicable to 47,351 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 327 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023. Read SEC document |
| December 27, 2023 Filed Dec 30, 2023 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCapped Value Appreciation Rights · Derivative | 85,232 | $6.40 | $545,484.80 |
DisclosureSEC source: 0001140361-23-060293 · form4.xml · derivative · entry 3 Gline Matthew · CIK 0001750094 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 994,373 Underlying: Common Shares · 38,126 shares Expires 2026-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount"). F2 · derivative.exercise_price: On December 27, 2023, the "knock-in" condition (as defined below) and hurdle price applicable to 85,232 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 38,126 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023. F5 · derivative.exercise_price: This award of CVARs vests (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date, with a vesting commencement date of December 27, 2019. F6 · derivative.exercise_price: In the event the fair market value of a Common Share is less than $9.20 per share as of the relevant date of determination (the "knock-in condition"), this award of CVARs will remain outstanding unless and until the knock-in condition is satisfied as of any applicable measurement date thereafter before the expiration date of the CVARs. F1 · shares: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount"). F2 · shares: On December 27, 2023, the "knock-in" condition (as defined below) and hurdle price applicable to 85,232 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 38,126 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023. F5 · shares: This award of CVARs vests (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date, with a vesting commencement date of December 27, 2019. F1 · price: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount"). F2 · price: On December 27, 2023, the "knock-in" condition (as defined below) and hurdle price applicable to 85,232 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 38,126 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023. F6 · price: In the event the fair market value of a Common Share is less than $9.20 per share as of the relevant date of determination (the "knock-in condition"), this award of CVARs will remain outstanding unless and until the knock-in condition is satisfied as of any applicable measurement date thereafter before the expiration date of the CVARs. F1 · derivative.exercise_date: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount"). F2 · derivative.exercise_date: On December 27, 2023, the "knock-in" condition (as defined below) and hurdle price applicable to 85,232 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 38,126 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023. F5 · derivative.exercise_date: This award of CVARs vests (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date, with a vesting commencement date of December 27, 2019. F1 · derivative.underlying_shares: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount"). F2 · derivative.underlying_shares: On December 27, 2023, the "knock-in" condition (as defined below) and hurdle price applicable to 85,232 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 38,126 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023. F6 · balance_after: In the event the fair market value of a Common Share is less than $9.20 per share as of the relevant date of determination (the "knock-in condition"), this award of CVARs will remain outstanding unless and until the knock-in condition is satisfied as of any applicable measurement date thereafter before the expiration date of the CVARs. Read SEC document |
| December 27, 2023 Filed Dec 30, 2023 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 22,043 | $11.58 | $255,257.94 |
DisclosureSEC source: 0001140361-23-060293 · form4.xml · nonDerivative · entry 2 Gline Matthew · CIK 0001750094 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,022,898 F4 · kind: Represents the "net settlement" by the Issuer of CVARs in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of the CVARs. Read SEC document |
| December 27, 2023 Filed Dec 30, 2023 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 38,453 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-23-060293 · form4.xml · nonDerivative · entry 1 Gline Matthew · CIK 0001750094 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,044,941 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount"). F2 · kind: On December 27, 2023, the "knock-in" condition (as defined below) and hurdle price applicable to 85,232 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 38,126 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023. F3 · kind: On December 27, 2023, the hurdle price applicable to 47,351 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 327 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023. F1 · price: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount"). F2 · price: On December 27, 2023, the "knock-in" condition (as defined below) and hurdle price applicable to 85,232 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 38,126 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023. F3 · price: On December 27, 2023, the hurdle price applicable to 47,351 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 327 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.